초대용량 웨어러블 인젝터 시장 : 적응증별(당뇨병, 자가면역질환, 종양, 기타) - 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2022-2031년)

The report provides revenue of the global ultra-large volume wearable injectors market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ultra-large volume wearable injectors market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ultra-large volume wearable injectors market.

The report delves into the competitive landscape of the global ultra-large volume wearable injectors market. Key players operating in the global ultra-large volume wearable injectors market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ultra-large volume wearable injectors market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Ultra-large Volume Wearable Injectors Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Indication Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Industry Developments
• 5.3. Ultra-large Volume Wearable Injectors Overview
• 5.4. COVID-19 Pandemics Impact on Industry

6. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, by Indication

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Indication, 2017-2031
  • 6.3.1. Diabetes
  • 6.3.2. Autoimmune Diseases
  • 6.3.3. Oncology
  • 6.3.4. Others
• 6.4. Market Attractiveness, by Indication

7. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 7.3.1. Retail Pharmacies & Drug stores
  • 7.3.2. E-commerce
  • 7.3.3. Others
• 7.4. Market Attractiveness, by Distribution Channel

8. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness, by Region

9. North America Ultra-large Volume Wearable Injectors Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast, by Indication, 2017-2031
  • 9.2.1. Diabetes
  • 9.2.2. Autoimmune Diseases
  • 9.2.3. Oncology
  • 9.2.4. Others
• 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.3.1. Retail Pharmacies & Drug stores
  • 9.3.2. E-commerce
  • 9.3.3. Others
• 9.4. Market Value Forecast, by Country, 2017-2031
  • 9.4.1. U.S.
  • 9.4.2. Canada
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Indication
  • 9.5.2. By Distribution Channel
  • 9.5.3. By Country

10. Europe Ultra-large Volume Wearable Injectors Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Indication, 2017-2031
  • 10.2.1. Diabetes
  • 10.2.2. Autoimmune Diseases
  • 10.2.3. Oncology
  • 10.2.4. Others
• 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.3.1. Retail Pharmacies & Drug stores
  • 10.3.2. E-commerce
  • 10.3.3. Others
• 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.4.1. Germany
  • 10.4.2. U.K.
  • 10.4.3. France
  • 10.4.4. Italy
  • 10.4.5. Spain
  • 10.4.6. Rest of Europe
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Indication
  • 10.5.2. By Distribution Channel
  • 10.5.3. By Country/Sub-region

11. Asia Pacific Ultra-large Volume Wearable Injectors Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Indication, 2017-2031
  • 11.2.1. Diabetes
  • 11.2.2. Autoimmune Diseases
  • 11.2.3. Oncology
  • 11.2.4. Others
• 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.3.1. Retail Pharmacies & Drug stores
  • 11.3.2. E-commerce
  • 11.3.3. Others
• 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.4.1. China
  • 11.4.2. Japan
  • 11.4.3. India
  • 11.4.4. Australia & New Zealand
  • 11.4.5. Rest of Asia Pacific
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Indication
  • 11.5.2. By Distribution Channel
  • 11.5.3. By Country/Sub-region

12. Latin America Ultra-large Volume Wearable Injectors Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Indication, 2017-2031
  • 12.2.1. Diabetes
  • 12.2.2. Autoimmune Diseases
  • 12.2.3. Oncology
  • 12.2.4. Others
• 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.3.1. Retail Pharmacies & Drug stores
  • 12.3.2. E-commerce
  • 12.3.3. Others
• 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.4.1. Brazil
  • 12.4.2. Mexico
  • 12.4.3. Rest of Latin America
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Indication
  • 12.5.2. By Distribution Channel
  • 12.5.3. By Country/Sub-region

13. Middle East & Africa Ultra-large Volume Wearable Injectors Market Analysis and Forecast

. Introduction

• 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Indication, 2017-2031
  • 13.2.1. Diabetes
  • 13.2.2. Autoimmune Diseases
  • 13.2.3. Oncology
  • 13.2.4. Others
• 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.3.1. Retail Pharmacies & Drug stores
  • 13.3.2. E-commerce
  • 13.3.3. Others
• 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.4.1. GCC Countries
  • 13.4.2. South Africa
  • 13.4.3. Rest of Middle East & Africa
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Indication
  • 13.5.2. By Distribution Channel
  • 13.5.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 14.2. Company Profiles
  • 14.2.1. Becton, Dickinson and Company
    • 14.2.1.1. Company Overview
    • 14.2.1.2. Financial Overview
    • 14.2.1.3. Product Portfolio
    • 14.2.1.4. SWOT Analysis
    • 14.2.1.5. Strategic Overview
  • 14.2.2. Buhler Motor GmbH
    • 14.2.2.1. Company Overview
    • 14.2.2.2. Financial Overview
    • 14.2.2.3. Product Portfolio
    • 14.2.2.4. SWOT Analysis
    • 14.2.2.5. Strategic Overview
  • 14.2.3. West Pharmaceutical Services, Inc.
    • 14.2.3.1. Company Overview
    • 14.2.3.2. Financial Overview
    • 14.2.3.3. Product Portfolio
    • 14.2.3.4. SWOT Analysis
    • 14.2.3.5. Strategic Overview
  • 14.2.4. Ypsomed AG
    • 14.2.4.1. Company Overview
    • 14.2.4.2. Financial Overview
    • 14.2.4.3. Product Portfolio
    • 14.2.4.4. SWOT Analysis
    • 14.2.4.5. Strategic Overview
  • 14.2.5. Medtronic
    • 14.2.5.1. Company Overview
    • 14.2.5.2. Financial Overview
    • 14.2.5.3. Product Portfolio
    • 14.2.5.4. SWOT Analysis
    • 14.2.5.5. Strategic Overview
  • 14.2.6. Sonceboz
    • 14.2.6.1. Company Overview
    • 14.2.6.2. Financial Overview
    • 14.2.6.3. Product Portfolio
    • 14.2.6.4. SWOT Analysis
    • 14.2.6.5. Strategic Overview
  • 14.2.7. Enable Injections
    • 14.2.7.1. Company Overview
    • 14.2.7.2. Financial Overview
    • 14.2.7.3. Product Portfolio
    • 14.2.7.4. SWOT Analysis
    • 14.2.7.5. Strategic Overview
  • 14.2.8. Subcuject Aps
    • 14.2.8.1. Company Overview
    • 14.2.8.2. Financial Overview
    • 14.2.8.3. Product Portfolio
    • 14.2.8.4. SWOT Analysis
    • 14.2.8.5. Strategic Overview
  • 14.2.9. Nemera
    • 14.2.9.1. Company Overview
    • 14.2.9.2. Financial Overview
    • 14.2.9.3. Product Portfolio
    • 14.2.9.4. SWOT Analysis
    • 14.2.9.5. Strategic Overview
  • 14.2.10. Eitan Medical
    • 14.2.10.1. Company Overview
    • 14.2.10.2. Financial Overview
    • 14.2.10.3. Product Portfolio
    • 14.2.10.4. SWOT Analysis
    • 14.2.10.5. Strategic Overview
  • 14.2.11. Weibel CDS AG
    • 14.2.11.1. Company Overview
    • 14.2.11.2. Financial Overview
    • 14.2.11.3. Product Portfolio
    • 14.2.11.4. SWOT Analysis
    • 14.2.11.5. Strategic Overview
  • 14.2.12. Gerresheimer AG
    • 14.2.12.1. Company Overview
    • 14.2.12.2. Financial Overview
    • 14.2.12.3. Product Portfolio
    • 14.2.12.4. SWOT Analysis
    • 14.2.12.5. Strategic Overview